Preclinical Data Suggest BET Plus PARP Inhibition May Treat Pancreatic Cancer

Share this content:
Preclinical data suggest that a BET inhibitor plus a PARP inhibitor may be a promising new approach to treat pancreatic cancer.
Preclinical data suggest that a BET inhibitor plus a PARP inhibitor may be a promising new approach to treat pancreatic cancer.

The combination of a BET and poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors decreased pancreatic ductal adenocarcinoma (PDAC) growth in preclinical models and may provide a novel approach to treatment, according to a study presented at the 2018 AACR Pancreatic Cancer: Advances in Science and Clinical Care conference in Boston, Massachusetts.1

Prior studies have suggested that the BET inhibitor JQ1 downregulates the expression of BET-dependent genes. Though JQ1 decreases PDAC tumor growth in animal models, the responses are not durable when it is used as monotherapy. Other studies also have suggested that JQ1 promotes DNA damage by inhibiting DNA repair, causing DNA repair deficiency. Therefore, the investigators hypothesized that the JQ1 would sensitize PDAC tumor cells to the PARP inhibitor olaparib.

This study treated 2 independent animal models with JQ1 plus olaparib; JQ1 or olaparib monotherapy; or vehicle control.

JQ1 plus olaparib significantly decreased PDAC tumor growth compared with JQ1 or olaparib monotherapy (P < .0001) or vehicle control (P < .05). There was an 8- to 33-fold increase in JQ1-induced DNA damage and a 54% to 90% inhibition of Ku80 and Rad51 with the combination treatment, as determined by immunoblot and immunohistochemistry analyses.

The investigators concluded that these data suggest that “combining a BET inhibitor with a PARP inhibitor may represent a novel approach for the treatment of PDAC.”

Reference

  1. Miller A, Fehling SC, Gamblin TL, et al. Combining the BET inhibitor JQ1 with the PARP inhibitor olaparib as a potential treatment for pancreatic ductal adenocarcinoma. Presented at: AACR Pancreatic Cancer: Advances in Science and Clinical Care; September 21-24, 2018; Boston, Massachusetts. Abstract A066.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs